Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques

Dali Tong; Mei Zhang; Yunru Yang; Han Xia; Haiyang Tong; Huajun Zhang; Weihong Zeng; Muziying Liu; Yan Wu; Huan Ma; Xue Hu; Weiyong Liu; Yuan Cai; Yanfeng Yao; Yichuan Yao; Kunpeng Liu; Shifang Shan; Yajuan Li; Ge Gao; Weiwei Guo; Yun Peng; Shaohong Chen; Juhong Rao; Jiaxuan Zhao; Juan Min; Qingjun Zhu; Yanmin Zheng; Lianxin Liu; Chao Shan; Kai Zhong; Zilong Qiu; Tengchuan Jin; Sandra Chiu; Zhiming Yuan; Tian Xue

doi:10.1093/procel/pwac020

PDF(1814 KB)

Protein Cell ›› 2023, Vol. 14 ›› Issue (1) : 69-73. DOI: 10.1093/procel/pwac020

LETTER

Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques

Dali Tong¹ ,
Mei Zhang¹^,² ,
Yunru Yang¹^,² ,
Han Xia³^,⁴ ,
Haiyang Tong⁵ ,
Huajun Zhang⁴ ,
Weihong Zeng² ,
Muziying Liu⁶ ,
Yan Wu⁴ ,
Huan Ma² ,
Xue Hu³ ,
Weiyong Liu¹ ,
Yuan Cai¹ ,
Yanfeng Yao⁴ ,
Yichuan Yao¹^,² ,
Kunpeng Liu³ ,
Shifang Shan⁷ ,
Yajuan Li⁸ ,
Ge Gao⁴ ,
Weiwei Guo³ ,
Yun Peng⁴ ,
Shaohong Chen³ ,
Juhong Rao³ ,
Jiaxuan Zhao³ ,
Juan Min⁴ ,
Qingjun Zhu⁵ ,
Yanmin Zheng⁵ ,
Lianxin Liu¹ ,
Chao Shan³ ,
Kai Zhong⁵ ,
Zilong Qiu⁷ ,
Tengchuan Jin¹^,² ,
Sandra Chiu¹^,² ,
Zhiming Yuan⁴ ,
Tian Xue¹^,²^,⁷^,⁹

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Dali Tong, Mei Zhang, Yunru Yang, Han Xia, Haiyang Tong, Huajun Zhang, Weihong Zeng, Muziying Liu, Yan Wu, Huan Ma, Xue Hu, Weiyong Liu, Yuan Cai, Yanfeng Yao, Yichuan Yao, Kunpeng Liu, Shifang Shan, Yajuan Li, Ge Gao, Weiwei Guo, Yun Peng, Shaohong Chen, Juhong Rao, Jiaxuan Zhao, Juan Min, Qingjun Zhu, Yanmin Zheng, Lianxin Liu, Chao Shan, Kai Zhong, Zilong Qiu, Tengchuan Jin, Sandra Chiu, Zhiming Yuan, Tian Xue. Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques. Protein Cell, 2023, 14(1): 69‒73 https://doi.org/10.1093/procel/pwac020

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Cohn BA , Cirillo PM , Murphy CC et al. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 2022; 375: 331- 336.

[2]	Daya S , Berns KI . Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583- 593.

[3]	Demminger DE , Walz L , Dietert K et al. Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcgamma receptor-activating antibodies. EMBO Mol Med 2020; 12: e10938.

[4]	Greig JA , Peng H , Ohlstein J et al. Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS One 2014; 9: e112268.

[5]	Krammer F . SARS-CoV-2 vaccines in development. Nature 2020; 586: 516- 527.

[6]	Li C , Narkbunnam N , Samulski RJ et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 2012; 19: 288- 294.

[7]	Ma H , Zeng W , Meng X et al. Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain. J Virol 2021; 95: e02438- 20.

[8]	Polack FP , Thomas SJ , Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603- 2615.

[9]	Shang J , Wan Y , Luo C et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA 2020; 117: 11727- 11734.

[10]	Wang D , Tai PWL , Gao G . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 2019; 18: 358- 378.

[11]	Yang J , Wang W , Chen Z et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020; 586: 572- 577.

[12]	Zhang Y , Zeng G , Pan H et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21: 181- 192.

[13]	Zhu FC , Guan XH , Li YH et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396: 479- 488.